drugset
drugset / Trial / NCT02963311

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT02963311 ↗

Phase 2 Completed 9 enrolled The Medicines Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.

Timeline

Start
2016-12-13
Primary completion
2018-10-08
Completion
2018-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Inclisiran Small interfering RNA (siRNA) 300 mg Subcutaneous

Indications

homozygous familial hypercholesterolemia